Clinical Trial Update: TAK-071 Scopolamine-Induced Cognitive Impairment Study [Phase 1]

View source ↗

Summary

Phase 1 trial update for TAK-071 investigating scopolamine-induced cognitive impairment in healthy volunteers; study terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthy Volunteers

Drugs mentioned

• TAK-071

Snippet

Sponsor: Takeda | Conditions: Healthy Volunteers | Phase 1 | Status: TERMINATED | Results posted: 2019-06-14